Evidence map›Paper›PMID 40770075›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2025

Cardiovascular risk of gender-affirming estrogen therapy in a transgender rat model.

D S Escudero, V R Martínez, Y Pirosanto, G A Colareda, M Pis Diez, J M Lofeudo, O Castillo, J O Vélez Rueda, E L Portiansky, N G Pérez and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

D S EscuderoCentro de Investigaciones Cardiovasculares Dr. Horacio E. Cingolani, Universidad Nacional de La Plata, Facultad de Ciencias Médicas de La Plata, Calle 60 y 120La Plata, 1900, Buenos Aires, Argentina.
V R MartínezCentro de Investigaciones Cardiovasculares Dr. Horacio E. Cingolani, Universidad Nacional de La Plata, Facultad de Ciencias Médicas de La Plata, Calle 60 y 120La Plata, 1900, Buenos Aires, Argentina.
Y PirosantoCentro de Investigaciones Cardiovasculares Dr. Horacio E. Cingolani, Universidad Nacional de La Plata, Facultad de Ciencias Médicas de La Plata, Calle 60 y 120La Plata, 1900, Buenos Aires, Argentina.
G A ColaredaPharmacology-GFEYEC, Facultad de Ciencias Exactas, Universidad Nacional de La Plata (UNLP), La Plata, Buenos Aires, Argentina.
M Pis DiezCentro de Investigaciones Cardiovasculares Dr. Horacio E. Cingolani, Universidad Nacional de La Plata, Facultad de Ciencias Médicas de La Plata, Calle 60 y 120La Plata, 1900, Buenos Aires, Argentina.
J M LofeudoCentro de Investigaciones Cardiovasculares Dr. Horacio E. Cingolani, Universidad Nacional de La Plata, Facultad de Ciencias Médicas de La Plata, Calle 60 y 120La Plata, 1900, Buenos Aires, Argentina.
O CastilloCentro de Investigaciones Cardiovasculares Dr. Horacio E. Cingolani, Universidad Nacional de La Plata, Facultad de Ciencias Médicas de La Plata, Calle 60 y 120La Plata, 1900, Buenos Aires, Argentina.
J O Vélez RuedaPhysiology and Biophysics, Facultad de Ciencias Médicas, Universidad Nacional de La Plata (UNLP), La Plata, Buenos Aires, Argentina.
E L PortianskyLaboratorio de Análisis de Imágenes, Facultad de Ciencias Veterinarias, Universidad Nacional de La Plata, La Plata, Buenos Aires, Argentina.
N G PérezCentro de Investigaciones Cardiovasculares Dr. Horacio E. Cingolani, Universidad Nacional de La Plata, Facultad de Ciencias Médicas de La Plata, Calle 60 y 120La Plata, 1900, Buenos Aires, Argentina.
R G DíazCentro de Investigaciones Cardiovasculares Dr. Horacio E. Cingolani, Universidad Nacional de La Plata, Facultad de Ciencias Médicas de La Plata, Calle 60 y 120La Plata, 1900, Buenos Aires, Argentina. rgdiaz@med.unlp.edu.ar.ORCID http://orcid.org/0000-0003-0599-510X

Funding

Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación PICT 2021-0300Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación (AR) PICT-I-A-00637CONICET (AR) PIP0418
6 · The paper itself

Abstract

The purpose of this study was to investigate the poorly understood cardiovascular effects of estrogen therapy (ET) in a transgender female (TGF) rat model of hypertension. This study provides novel insights into the potential risks and benefits of gender-affirming hormone therapy (GAHT). Three-month-old male spontaneously hypertensive rats were gonadectomized, and 2 months later were randomly assigned to two different groups: GDX (3-month gonadectomy) and TGF (subcutaneous 10 μg/0.2 ml estradiol cypionate treatment every 4 days for 1 month). An age-matched control group received surgical anesthesia and vehicle (filtered corn oil) injections for the same time period (SHAM). Testosterone deprivation promoted a reduction in cardiac hypertrophy that was canceled by ET without changes in blood pressure. Echocardiographic analysis revealed different types of cardiac remodeling among groups. Isolated left ventricle papillary muscles of GDX exhibited greater stiffness than SHAM or TGF. Contractility of these muscles was reduced in TGF, showing higher response to extracellular calcium increase. An alteration in calcium handling protein expressions was observed. Oxidative stress was higher in GDX myocardium, and ET reversed this effect. Nitric oxide production increased in TGF hearts. White adipose tissue index increased in TGF without affecting body weight, and plasma cholesterol levels followed the same pattern. ET in TGF comprises a complex scenario characterized by high cardiovascular risk, reduced contractility presumably linked to changes in calcium handling proteins, and similar redox status probably due to compensatory mechanisms. Altogether, these findings have implications for long-term cardiovascular health prognosis of transgender patients and emphasize the need for further research to optimize GAHT. KEY MESSAGES: Clinical evidence suggests an increase in cardiovascular risk with GAHT, but evidence is limited. We developed a transgender female animal model that fosters unbiased research. Cardiovascular remodeling in hypertension is strongly related with circulating testosterone even in transgender females. Estrogen therapy in transgender female rats compensates ROS and myocardial distensibility. Estrogen therapy in transgender female rats worsens lipid management and cardiac contractility.

Indexed as

Cardiovascular DiseasesEstradiolEstrogen Replacement TherapyEstrogensAnimalsBlood PressureDisease Models, AnimalFemaleHypertensionMaleOxidative StressRatsRats, Inbred SHRTestosteroneVentricular RemodelingEstradiolEstrogensTestosteroneCardiac contractilityCardiac hypertrophyGender-affirming estrogen therapyHypertensionTransgender health

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.